Daiichi Sankyo Company, Limited (TYO: 4568) announced that Enhertu (trastuzumab deruxtecan) has officially been approved in China as a monotherapy for adult patients with unresectable or metastatic HER2‑expressing (IHC 3+) solid tumors who have received prior treatment or have no satisfactory alternative treatment options. The approval marks China’s first tumor‑agnostic HER2‑targeted therapy, granted as a conditional approval based on results from single‑arm clinical trials – a landmark for precision oncology in the Chinese market.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | China (national regulator) |
| Approval Type | Conditional approval, based on single‑arm clinical trials |
| Product | Enhertu (trastuzumab deruxtecan) – monotherapy |
| Indication | Adults with unresectable or metastatic HER2‑expressing (IHC 3+) solid tumors who received prior treatment or have no satisfactory alternative options |
| Approval Date | 22 Oct 2026 (announcement) |
| Distinction | First tumor‑agnostic HER2‑targeted therapy approved in China |
| Supporting Trials | Four Phase II studies: DESTINY‑PanTumor02, DESTINY‑Lung01, DESTINY‑CRC02, DESTINY‑PanTumor03 |
Drug Profile & Mechanism of Action
- Molecule: Trastuzumab deruxtecan, a HER2‑directed antibody‑drug conjugate (ADC).
- Platform: Designed using Daiichi Sankyo’s proprietary DXd ADC technology – the lead product in Daiichi Sankyo’s oncology portfolio and the most advanced project in AstraZeneca’s ADC platform.
- Structural Design: A HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a cleavable tetrapeptide‑based linker.
- Tumor‑Agnostic Concept: Rather than being restricted to one organ of origin, the therapy targets HER2 expression (IHC 3+) as the biomarker across solid tumor types – enabling a single indication to span multiple cancers.
Clinical Evidence – Four Phase II DESTINY Trials
| Trial | Focus / Tumor Types | Result |
|---|---|---|
| DESTINY‑PanTumor02 | Broad range of HER2‑expressing solid tumors | Clinically meaningful responses across tumor types (individual response rates not disclosed) |
| DESTINY‑Lung01 | HER2‑mutant/expressing lung cancer | Clinically meaningful responses (details not disclosed) |
| DESTINY‑CRC02 | HER2‑expressing colorectal cancer | Clinically meaningful responses (details not disclosed) |
| DESTINY‑PanTumor03 | Pan‑tumor HER2‑expressing population | Clinically meaningful responses (details not disclosed) |
The approval is based on results from the four Phase II clinical trials, in which trastuzumab deruxtecan demonstrated clinically meaningful responses across a broad range of tumor types – the evidentiary foundation for a tumor‑agnostic indication covering any HER2‑expressing (IHC 3+) solid tumor meeting the treatment‑history criteria.
Market Impact & Outlook
- First‑in‑Class in China: As China’s first tumor‑agnostic HER2‑targeted therapy, Enhertu establishes a new regulatory and commercial paradigm – biomarker‑driven rather than organ‑driven oncology treatment in the Chinese market.
- ADC Franchise Expansion: The approval extends the Enhertu/DXd ADC franchise – already a cornerstone of the Daiichi Sankyo–AstraZeneca oncology alliance – into the world’s second‑largest pharmaceutical market with a pan‑tumor label.
- Broad Addressable Population: HER2 expression occurs across numerous solid tumor types; a single tumor‑agnostic indication potentially reaches patients with lung, colorectal, biliary, gynecologic, and other HER2‑expressing cancers who have exhausted standard options.
- Conditional Approval Framework: Granted on single‑arm trial evidence, the indication carries China’s conditional‑approval obligations, with confirmatory data expected under regulatory requirements (specific conditions and timelines not disclosed).
- Next Steps: Commercial launch execution in China and any further tumor‑specific or line‑of‑therapy expansions were not disclosed beyond this announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Enhertu’s conditional approval in China, clinical benefits observed in the DESTINY trial program, and commercial potential in HER2‑expressing solid tumors. Conditional approval is subject to ongoing obligations and confirmatory evidence requirements. Actual results may differ materially due to risks including regulatory conditions, real‑world clinical experience, pricing and reimbursement decisions in China, and competitive therapies.-Fineline Info & Tech
